# HRD and Resistance to PAPPi in EOC Patients

> **NCT05310370** · — · UNKNOWN · sponsor: **Lei Li** · enrollment: 400 (estimated)

## Conditions studied

- Epithelial Ovarian Cancer
- Homologous Recombination Deficiency
- Homologous Recombination Repair Gene Mutation
- Poly(ADP-ribose) Polymerase Inhibitor
- Drug Resistance
- Progression-free Survival
- Overall Survival

## Interventions

- **GENETIC:** Testing of homologous recombination deficiency

## Key facts

- **NCT ID:** NCT05310370
- **Lead sponsor:** Lei Li
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-26
- **Primary completion:** 2024-03-26
- **Final completion:** 2025-03-26
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2022-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05310370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05310370, "HRD and Resistance to PAPPi in EOC Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05310370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*